EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Predicting 10‐year risk of type 2 diabetes in Chinese people with overweight or obesity treated with Tirzepatide: Post hoc analysis of SURMOUNT ‐ CN trial

Lin Zhao, Feng Tao, Zhifeng Cheng, Yibing Lu, Ming Liu, Hong Chen, Min Zhang, Yang Yang, Xiang Song, Yuzi Sun, Xiao Ma, Si Si und 2 weitere

Diabetes, Obesity and Metabolism · 2025

DOI: 10.1111/dom.16439 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Diabetes, Obesity and Metabolism, 2025. Verfasst von Lin Zhao und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology and Metabolism, Zhongshan Hospital, Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Overweight, Obesity, Tirzepatide. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 32 Literaturangaben. Gefördert von: Eli Lilly and Company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

To assess the association of tirzepatide use with a 10‐year predicted risk of type 2 diabetes (T2D) among Chinese participants with obesity or overweight from the SURMOUNT‐CN trial. Materials and Methods In this post hoc analysis, the QDiabetes‐2018 risk engine was used to calculate the 10‐year predicted T2D risk at baseline, week 24 and week 52 among SURMOUNT‐CN participants randomized to receive tirzepatide 10 mg, 15 mg or placebo. A mixed model for repeated measures was used to compare mean predicted risk changes from baseline to weeks 24 and 52 between tirzepatide and placebo. Subgroup analyses were conducted by baseline body weight mass index (BMI) status and baseline prediabetes status.

Results

Demographic and baseline clinical characteristics were similar among tirzepatide10 mg ( n = 59), 15 mg ( n = 53) and placebo ( n = 57). From baseline to week 52, the least square (LS) mean predicted T2D risk changed from 5.3% to 1.2% for tirzepatide 10 mg, from 4.9% to 1.0% for tirzepatide 15 mg and from 5.8% to 4.5% for placebo. The difference in LS mean risk change from baseline to week 52 was significant between both tirzepatide 10 mg (−3.2%, 95% confidence interval [CI]: −4.2%, −2.2%) and 15 mg (−3.4%, 95% CI: −4.4%, −2.4%) and placebo. Significantly greater predicted risk reductions for tirzepatide than placebo were observed in all subgroups.

Conclusion

Tirzepatide was associated with significantly reduced predicted 10‐year risk of T2D among SURMOUNT‐CN participants with obesity or overweight, irrespective of baseline BMI and prediabetes status.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2OverweightObesityTirzepatideHumansFemaleMaleMiddle AgedAdultChinaRisk FactorsBody Mass IndexDouble-Blind MethodPrediabetic StateRisk AssessmentAgedEast Asian People

Stichwörter der Autor:innen

obesityprediabetesrisk predictiontirzepatidetype 2 diabetes

Substanzen

Tirzepatide

Autor:innen und Institutionen

  • Department of Endocrinology and Metabolism, Zhongshan Hospital, Fudan University, Shanghai, China.
  • Department of Endocrinology, Shanghai Traditional Chinese Medicine Hospital, Shanghai, China.
  • Department of Endocrinology, Fourth Affiliated Hospital of Harbin Medical University, Harbin, China.
  • Department of Endocrinology, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, China.
  • Department of Endocrinology and Metabolism, Tianjin Medical University General Hospital, Tianjin, China.
  • Department of Endocrinology, Zhujiang Hospital, Southern Medical University, Guangzhou, China.

ORCID-Profile: Hanxi Zhang, Xiaoying Li

Förderung

  • Eli Lilly and Company

Zitieren

APA

Zhao, L., Tao, F., Cheng, Z., Lu, Y., Liu, M., Chen, H., Zhang, M., Yang, Y., Song, X., Sun, Y., Ma, X., Si, S., Zhang, H., & Li, X. (2025). Predicting 10‐year risk of type 2 diabetes in Chinese people with overweight or obesity treated with Tirzepatide: Post hoc analysis of SURMOUNT ‐ CN trial. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.16439

Vancouver

Zhao L, Tao F, Cheng Z, Lu Y, Liu M, Chen H, et al. Predicting 10‐year risk of type 2 diabetes in Chinese people with overweight or obesity treated with Tirzepatide: Post hoc analysis of SURMOUNT ‐ CN trial. Diabetes, Obesity and Metabolism. 2025. doi:10.1111/dom.16439

BibTeX
@article{Zhao2025,
  author = {Zhao, Lin and Tao, Feng and Cheng, Zhifeng and Lu, Yibing and Liu, Ming and Chen, Hong and Zhang, Min and Yang, Yang and Song, Xiang and Sun, Yuzi and Ma, Xiao and Si, Si and Zhang, Hanxi and Li, Xiaoying},
  title = {Predicting 10‐year risk of type 2 diabetes in Chinese people with overweight or obesity treated with Tirzepatide: Post hoc analysis of SURMOUNT ‐ CN trial},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2025},
  doi = {10.1111/dom.16439}
}
Kostenlos starten →